Volgen
Michel Tsang-A-Sjoe
Michel Tsang-A-Sjoe
Onbekend partnerschap
Geverifieerd e-mailadres voor vumc.nl
Titel
Geciteerd door
Geciteerd door
Jaar
Both prolonged remission and Lupus Low Disease Activity State are associated with reduced damage accrual in systemic lupus erythematosus
MWP Tsang-A-Sjoe, IEM Bultink, M Heslinga, AE Voskuyl
Rheumatology, kew377, 2016
1022016
Fc-gamma receptor polymorphisms differentially influence susceptibility to systemic lupus erythematosus and lupus nephritis
MWP Tsang-A-Sjoe, SQ Nagelkerke, IEM Bultink, J Geissler, MWT Tanck, ...
Rheumatology 55 (5), 939-948, 2016
522016
2021 DORIS definition of remission in SLE: final recommendations from an international task force
RF van Vollenhoven, G Bertsias, A Doria, D Isenberg, E Morand, MA Petri, ...
Lupus Science & Medicine 8 (1), e000538, 2021
412021
B-cell imaging with zirconium-89 labelled rituximab PET-CT at baseline is associated with therapeutic response 24 weeks after initiation of rituximab treatment in rheumatoid …
S Bruijnen, H Raterman, T Ramwadhdoebe, D Vugts, G van Dongen, ...
Arthritis research & therapy 18 (1), 1-8, 2016
292016
Treatment targets in SLE: remission and low disease activity state
V Golder, MWP Tsang-A-Sjoe
Rheumatology 59 (Supplement_5), v19-v28, 2020
242020
The relationship between remission and health-related quality of life in a cohort of SLE patients
MWP Tsang-A-Sjoe, IEM Bultink, M Heslinga, LH van Tuyl, ...
Rheumatology 58 (4), 628-635, 2019
242019
Anti-hinge antibodies recognize IgG subclass–and protease-restricted neoepitopes
WJJ Falkenburg, D Van Schaardenburg, P Ooijevaar-de Heer, ...
The Journal of Immunology 198 (1), 82-93, 2017
242017
A multi-parameter response prediction model for rituximab in rheumatoid arthritis
TD de Jong, J Sellam, R Agca, S Vosslamber, BI Witte, M Tsang-A-Sjoe, ...
Joint Bone Spine 85 (2), 219-226, 2018
192018
Systemic lupus erythematosus: review of synthetic drugs
MWP Tsang-A-Sjoe, IEM Bultink
Expert Opinion on Pharmacotherapy 16 (18), 2793-2806, 2015
182015
Long-term evaluation of antimalarials in a Dutch SLE cohort: intolerance and other reasons for non-use
MW Tsang-A-Sjoe, IE Bultink, AE Voskuyl
Clin Exp Rheumatol 32 (1), 95-100, 2014
152014
Pharmacodynamic monitoring of (immuno) proteasome inhibition during bortezomib treatment of a critically ill patient with lupus nephritis and myocarditis
KA de Groot, MT a Sjoe, D Niewerth, J Cloos, JL Blank, HWM Niessen, ...
Lupus Science & Medicine 2 (1), e000121, 2015
112015
Comprehensive approach to study complement C4 in systemic lupus erythematosus: gene polymorphisms, protein levels and functional activity
MWP Tsang-A-Sjoe, IEM Bultink, LA Korswagen, A van der Horst, ...
Molecular Immunology 92, 125-131, 2017
102017
New developments in systemic lupus erythematosus
MWP Tsang-A-Sjoe, IEM Bultink
Rheumatology 60 (Supplement_6), vi21-vi28, 2021
42021
Unexpected severe incident vertebral fractures in patients with systemic lupus erythematosus: comment on the article by Zhu et al.
J Jacobs, MWP Tsang A Sjoe, AE Voskuyl, WF Lems, IEM Bultink
Lupus 24 (2), 222-223, 2015
32015
S2D: 5 Exosomes target renal tubular epithelial cells transferring inflammatory epstein–barr virus-encoded small rna (eber1) in lupus nephritis patients
SR Baglio, N Masoumi, MW Tsang-a-Sjoe, MA van Eijndhoven, ...
Lupus Science & Medicine 5 (Suppl 1), 2018
12018
SAT0284 Both Prolonged Remission and Lupus Low Disease Activity State Are Associated with Reduced Damage Accrual in Systemic Lupus Erythematosus
MWP Tsang-A-Sjoe, IEM Bultink, M Heslinga, AE Voskuyl
Annals of the Rheumatic Diseases 75 (Suppl 2), 771-771, 2016
12016
A novel and effective prediction model of response to rituximab in rheumatoid arthritis
AM van Sijl, Tsang-A-Sjoe, Michel WP, HG Raterman, MT Nurmohamed, ...
ARTHRITIS AND RHEUMATISM 65, S1016-S1016, 2013
12013
Macrophages in Lupus Nephritis: Exploring a potential new therapeutic avenue
LE Kwant, Y Vegting, MWP Tsang-a-Sjoe, AJ Kwakernaak, L Vogt, ...
Autoimmunity Reviews, 103211, 2022
2022
PO. 8.167 Intercurrent infection as a risk factor for disease flares in patients with systemic lupus erythematosus
F El Hadiyen, M Tsang-A-Sjoe, B Lissenberg-Witte, A Voskuijl, I Bultink
Lupus Science & Medicine 9 (Suppl 2), 2022
2022
PO. 8.186 SLE-T2T–a digital treat-to-target clinical decision support system for the management of systemic lupus erythematosus patients: development and usability evaluation
AP Sanchez, MG Grimberg, MMA Hanssen, MO Aben, EE Jairth, ...
Lupus Science & Medicine 9 (Suppl 2), 2022
2022
Het systeem kan de bewerking nu niet uitvoeren. Probeer het later opnieuw.
Artikelen 1–20